M&A Deal Summary

AstraZeneca Acquires Gracell Biotechnologies

On December 26, 2023, AstraZeneca acquired life science company Gracell Biotechnologies for 1.2B USD

Acquisition Highlights
  • This is AstraZeneca’s 15th transaction in the Life Science sector.
  • This is AstraZeneca’s 8th largest (disclosed) transaction.
  • This is AstraZeneca’s 1st transaction in China.

M&A Deal Summary

Date 2023-12-26
Target Gracell Biotechnologies
Sector Life Science
Buyer(s) AstraZeneca
Deal Type Add-on Acquisition
Deal Value 1.2B USD

Target

Gracell Biotechnologies

Suzhou, China
website
Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. Gracell Biotechnologies was founded in 2017 and is based in Suzhou, China.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom

website


Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 45.8B USD (2023)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.


DEAL STATS #
Overall 17 of 19
Sector (Life Science) 15 of 17
Type (Add-on Acquisition) 13 of 15
Country (China) 1 of 1
Year (2023) 2 of 2
Size (of disclosed) 8 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-12 Icosavax

Seattle, Washington, United States

Icosavax is a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Icosavax was founded in 2017 and is based in Seattle, Washington.

Buy $1.1B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-14 Amolyt Pharma

Ecully, France

Amolyt Pharma is a clinical-stage biotechnology company, building therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma was founded in 2015 and is based in Ecully, France.

Buy $1.1B